<DOC>
	<DOCNO>NCT01273090</DOCNO>
	<brief_summary>RATIONALE : Imetelstat sodium may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I clinical trial study side effect best dose imetelstat sodium treat young patient refractory recurrent solid tumor lymphoma .</brief_summary>
	<brief_title>Imetelstat Sodium Treating Young Patients With Refractory Recurrent Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate maximum-tolerated dose ( MTD ) and/or recommend phase II dose imetelstat sodium child refractory recurrent solid tumor lymphoma . - To define describe toxicity imetelstat sodium . - To characterize pharmacokinetics imetelstat sodium child refractory recurrent solid tumor lymphoma . Secondary - To determine , preliminary manner , antitumor effect imetelstat sodium child refractory recurrent solid tumor lymphoma . ( exploratory ) - To provide preliminary assessment biological activity imetelstat sodium child recurrent refractory malignancy assess telomerase activity , telomere length , hTERT protein , hTERT mRNA , hTR level patient peripheral blood mononuclear cell ( PBMNC ) sample pretreatment treatment . ( Exploratory ) - To assess telomerase activity , hTERT expression , telomere length , hTERT protein , hTERT mRNA , hTR level patient ' pretreatment tumor sample . ( Exploratory ) OUTLINE : This multicenter , dose-escalation study . Patients receive imetelstat sodium IV 2 hour day 1 8 . Treatment repeat every 21 day 18 course absence disease progression unacceptable toxicity . Patients undergo blood sample collection baseline periodically study pharmacokinetic correlative study . Tumor tissue sample diagnosis and/or subsequent tumor resection biopsy may also collect correlative study . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis refractory recurrent solid tumor , include lymphoma No CNS tumor know CNS metastasis ( Part A , dose escalation ) CNS tumor know CNS metastasis allow ( Part B , maximumtolerated dose recommend phase II dose ) No prior concurrent CNS hemorrhage baseline MRI within past 14 day All patient must histologic verification malignancy original diagnosis relapse except : Intrinsic brain stem tumor Optic pathway glioma Pineal tumor elevation CSF serum tumor marker include alphafetoprotein betaHCG Measurable evaluable disease Disease know curative therapy therapy proven prolong survival acceptable quality life Patients know bone marrow metastatic disease eligible study provide meet blood count criterion know refractory red cell platelet transfusion PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 50100 % ( patient &gt; 16 year age ) OR Lansky PS 50100 % ( patient ≤ 16 year age ) ANC ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ ( transfusionindependent , define receive platelet transfusion within past 7 day prior enrollment ) Creatinine clearance radioisotope GFR ≥ 70 mL/min OR serum creatinine base age and/or gender follow : 0.6 mg/dL ( 1 &lt; 2 year age ) 0.8 mg/dL ( 2 &lt; 6 year age ) 1.0 mg/dL ( 6 &lt; 10 year age ) 1.2 mg/dL ( 10 &lt; 13 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( 13 &lt; 16 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( ≥ 16 year age ) Bilirubin ( sum conjugate unconjugated ) ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 110 U/L ( ULN ALT 45 U/L ) Serum albumin ≥ 2 g/dL aPTT &lt; 1.2 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception method No uncontrolled infection No patient , opinion investigator , may able comply safety monitoring requirement study PRIOR CONCURRENT THERAPY : Recovered acute toxic effect prior anticancer chemotherapy , immunotherapy , radiotherapy At least 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosourea ) At least 14 day since prior longacting growth factor ( e.g. , Neulasta ) ≥ 7 day since prior shortacting growth factor At least 7 day since prior biologic antineoplastic agent At least 6 week since type prior immunotherapy ( e.g. , tumor vaccine ) At least 3 halflives since last dose monoclonal antibody At least 2 week since prior local palliative radiotherapy ( small port ) At least 24 week since prior totalbody irradiation , craniospinal radiotherapy , radiation ≥ 50 % pelvis At least 6 week since prior substantial bone marrow radiation At least 12 week since prior transplantation stem cell infusion evidence active graft v host disease Prior concurrent stable decrease dose corticosteroid within past 7 day allow No prior allogeneic transplant No concurrent investigational drug No concurrent anticancer agent include chemotherapy , radiotherapy , immunotherapy , biologic therapy No concurrent cyclosporine , tacrolimus , agent prevent either graftversushost disease postbone marrow transplant organ rejection posttransplant</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood anaplastic astrocytoma</keyword>
	<keyword>recurrent childhood anaplastic oligoastrocytoma</keyword>
	<keyword>recurrent childhood anaplastic oligodendroglioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood diffuse astrocytoma</keyword>
	<keyword>recurrent childhood fibrillary astrocytoma</keyword>
	<keyword>recurrent childhood gemistocytic astrocytoma</keyword>
	<keyword>recurrent childhood giant cell glioblastoma</keyword>
	<keyword>recurrent childhood glioblastoma</keyword>
	<keyword>recurrent childhood gliomatosis cerebri</keyword>
	<keyword>recurrent childhood gliosarcoma</keyword>
	<keyword>recurrent childhood oligoastrocytoma</keyword>
	<keyword>recurrent childhood oligodendroglioma</keyword>
	<keyword>recurrent childhood pilocytic astrocytoma</keyword>
	<keyword>recurrent childhood pilomyxoid astrocytoma</keyword>
	<keyword>recurrent childhood pleomorphic xanthoastrocytoma</keyword>
	<keyword>recurrent childhood protoplasmic astrocytoma</keyword>
	<keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood visual pathway glioma</keyword>
	<keyword>childhood pineal parenchymal tumor</keyword>
	<keyword>recurrent childhood central nervous system embryonal tumor</keyword>
	<keyword>childhood central nervous system choriocarcinoma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood central nervous system germinoma</keyword>
	<keyword>childhood central nervous system mixed germ cell tumor</keyword>
	<keyword>childhood central nervous system teratoma</keyword>
	<keyword>childhood central nervous system yolk sac tumor</keyword>
	<keyword>recurrent childhood pineoblastoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>childhood nodular lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>hepatosplenic T-cell lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>noncutaneous extranodal lymphoma</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>small intestine lymphoma</keyword>
</DOC>